The selling stockholders may sell from time to time, pursuant to this prospectus supplement, an aggregate of up to 51,422,763 shares of our voting common stock, consisting of (a) 21,690,334 shares of voting common stock held by the Warburg Investors and the Centerbridge Investor, (b) 10,829,990 shares of voting common stock issuable upon the conversion of shares of non-voting common equivalent stock held by the Warburg Investors and the Bayview Investor (as defined below), (c) 3,048,780 shares of voting common stock issuable upon the exercise of a warrant issued to the Centerbridge Investor, and (d) 15,853,659 shares of voting common stock issuable upon the conversion of shares of the non-voting common equivalent stock, which are issuable upon the exercise of warrants issued to the Warburg Investors, each as further described below. We are registering these shares on behalf of the selling stockholders, to be offered and sold by them from time to time, to satisfy certain registration rights that we have granted to the selling stockholders under the Registration Rights Agreement.
Investment Agreements
On July 25, 2023, concurrently with our entry into the Merger Agreement, we entered into separate investment agreements (the “Investment Agreements”) with the Warburg Investors and the Centerbridge Investor.
On the terms and subject to the conditions set forth in the Investment Agreements, at the closing of the investments (as defined below) on November 30, 2023, the Warburg Investors and the Centerbridge Investor invested an aggregate of $400 million in exchange for the sale and issuance by us of (i) 21,690,334 shares of our voting common stock and (ii) 10,829,990 shares of our non-voting common-equivalent stock, in each case, at a purchase price of $12.30 per share. Subject to any applicable transfer restrictions in the Investment Agreements, each share of non-voting common equivalent stock will automatically convert into one share of voting common stock, subject to certain adjustments, when transferred (a) to us, (b) in a widespread public distribution, (c) in a transfer in which no transferee (or group of associated transferees) would receive 2% or more of the outstanding securities of any class of our voting securities or (d) to a purchaser that would control more than fifty percent (50%) of every class of our voting securities without any transfer from such holder of our non-voting common-equivalent stock.
In addition, pursuant to the Investment Agreements, the Warburg Investors received warrants to purchase 15,853,659 shares of our non-voting common equivalent stock, and the Centerbridge Investor received warrants to purchase 3,048,780 shares of our voting common stock, each with an exercise price of $15.375 per share, subject to customary anti-dilution adjustments provided under the warrants (collectively, the “warrants” and together with the voting common stock and the non-voting common-equivalent stock issued pursuant to the Investment Agreements, the “investments”). The warrants carry a term of seven years but are subject to mandatory exercise when the market price of our voting common stock reaches or exceeds $24.60 for 20 or more trading days during any 30-consecutive trading day period, a 100% premium to the price paid by the Warburg Investors and the Centerbridge Investor for our voting common stock and non-voting common equivalent stock. The warrants may be settled on a “net share” basis by applying shares otherwise issuable under the warrants in satisfaction of the exercise price.
Pursuant to the Investment Agreement with the Warburg Investors, so long as the Warburg Investors, together with their affiliates, beneficially own in the aggregate at least the lesser of (a) 5.0% of the outstanding shares of our voting common stock (on an as-converted basis), and (b) 50% of our voting common stock (on an as-converted basis and after giving effect to any Permitted Transfers (as defined therein)) that the Warburg Investors beneficially owned immediately following the closing of the investments, as adjusted from time to time for any reorganization, recapitalization, stock dividend, stock split, reverse stock split or other like changes in our capitalization, we agreed to (i) include a person nominated by the Warburg Investors to be appointed to our board of directors (the “Warburg director”) in our slate of director nominees and recommend to our stockholders that our stockholders vote in favor of electing the Warburg director to our board of directors at our annual meeting and (ii) use reasonable best efforts to have the Warburg director elected as a director of us, including soliciting proxies to the same extent as we do for any other nominee of our board of directors. Effective at the closing of the investments, Todd Schell, a nominee designated by the Warburg Investors, joined our board of directors.
Pursuant to the Investment Agreement with the Warburg Investors, until the 180-day anniversary of the closing of the investments, subject to certain exceptions, the Warburg Investors are prohibited from transferring 25% of the securities acquired pursuant to such agreement. The Warburg Investors are subject to certain additional transfer restrictions following the expiration of such 180-day period.
On November 30, 2023, immediately after the closing of the investments, the Warburg Investors transferred 2,032,520 shares of non-voting common equivalent stock to Bayview Opportunity Master Fund VII, L.P. (the